vs
Leonardo DRS, Inc.（DRS）与Royalty Pharma plc（RPRX）财务数据对比。点击上方公司名可切换其他公司
Leonardo DRS, Inc.的季度营收约是Royalty Pharma plc的1.7倍（$1.1B vs $622.0M），Royalty Pharma plc净利率更高（34.4% vs 9.6%，领先24.8%），Leonardo DRS, Inc.同比增速更快（8.1% vs 4.8%），过去两年Leonardo DRS, Inc.的营收复合增速更高（24.1% vs 4.6%）
莱昂纳多DRS公司是美国本土国防承包商，前身为DRS技术公司，曾于纽约证券交易所挂牌交易，2008年被莱昂纳多的前身芬梅卡尼卡收购，核心业务为向美国军方提供先进国防技术及配套系统产品。
本公司是总部位于美国马萨诸塞州剑桥市的临床阶段生物制药企业，专注于研发可调节转化生长因子β（TGF-β）超家族蛋白的药物，该类蛋白在红细胞、肌肉、骨骼、血管等细胞与组织的生长修复过程中发挥核心作用。
DRS vs RPRX — 直观对比
营收规模更大
DRS
是对方的1.7倍
$622.0M
营收增速更快
DRS
高出3.3%
4.8%
净利率更高
RPRX
高出24.8%
9.6%
两年增速更快
DRS
近两年复合增速
4.6%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $1.1B | $622.0M |
| 净利润 | $102.0M | $214.2M |
| 毛利率 | 25.4% | — |
| 营业利润率 | 11.9% | 62.4% |
| 净利率 | 9.6% | 34.4% |
| 营收同比 | 8.1% | 4.8% |
| 净利润同比 | 14.6% | 2.9% |
| 每股收益（稀释后） | $0.38 | $0.49 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收DRSRPRX
| Q4 25 | $1.1B | $622.0M | ||
| Q3 25 | $960.0M | $609.3M | ||
| Q2 25 | $829.0M | $578.7M | ||
| Q1 25 | $799.0M | $568.2M | ||
| Q4 24 | $981.0M | $593.6M | ||
| Q3 24 | $812.0M | $564.7M | ||
| Q2 24 | $753.0M | $537.3M | ||
| Q1 24 | $688.0M | $568.0M |
净利润DRSRPRX
| Q4 25 | $102.0M | $214.2M | ||
| Q3 25 | $72.0M | $288.2M | ||
| Q2 25 | $54.0M | $30.2M | ||
| Q1 25 | $50.0M | $238.3M | ||
| Q4 24 | $89.0M | $208.2M | ||
| Q3 24 | $57.0M | $544.0M | ||
| Q2 24 | $38.0M | $102.0M | ||
| Q1 24 | $29.0M | $4.8M |
毛利率DRSRPRX
| Q4 25 | 25.4% | — | ||
| Q3 25 | 23.1% | — | ||
| Q2 25 | 23.8% | — | ||
| Q1 25 | 22.7% | — | ||
| Q4 24 | 24.0% | — | ||
| Q3 24 | 22.0% | — | ||
| Q2 24 | 22.4% | — | ||
| Q1 24 | 22.2% | — |
营业利润率DRSRPRX
| Q4 25 | 11.9% | 62.4% | ||
| Q3 25 | 9.7% | 70.1% | ||
| Q2 25 | 8.4% | 36.3% | ||
| Q1 25 | 7.4% | 94.0% | ||
| Q4 24 | 12.2% | 60.9% | ||
| Q3 24 | 9.2% | — | ||
| Q2 24 | 7.3% | 50.2% | ||
| Q1 24 | 6.3% | -13.0% |
净利率DRSRPRX
| Q4 25 | 9.6% | 34.4% | ||
| Q3 25 | 7.5% | 47.3% | ||
| Q2 25 | 6.5% | 5.2% | ||
| Q1 25 | 6.3% | 41.9% | ||
| Q4 24 | 9.1% | 35.1% | ||
| Q3 24 | 7.0% | 96.3% | ||
| Q2 24 | 5.0% | 19.0% | ||
| Q1 24 | 4.2% | 0.8% |
每股收益（稀释后）DRSRPRX
| Q4 25 | $0.38 | $0.49 | ||
| Q3 25 | $0.26 | $0.67 | ||
| Q2 25 | $0.20 | $0.07 | ||
| Q1 25 | $0.19 | $0.55 | ||
| Q4 24 | $0.34 | $0.46 | ||
| Q3 24 | $0.21 | $1.21 | ||
| Q2 24 | $0.14 | $0.23 | ||
| Q1 24 | $0.11 | $0.01 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $647.0M | $618.7M |
| 总债务越低越好 | $321.0M | $9.0B |
| 股东权益账面价值 | $2.7B | $9.7B |
| 总资产 | $4.5B | $19.6B |
| 负债/权益比越低杠杆越低 | 0.12× | 0.92× |
8季度趋势，按日历期对齐
现金及短期投资DRSRPRX
| Q4 25 | $647.0M | $618.7M | ||
| Q3 25 | $309.0M | $938.9M | ||
| Q2 25 | $278.0M | $631.9M | ||
| Q1 25 | $380.0M | $1.1B | ||
| Q4 24 | $598.0M | $929.0M | ||
| Q3 24 | $198.0M | $950.1M | ||
| Q2 24 | $149.0M | $1.8B | ||
| Q1 24 | $160.0M | $843.0M |
总债务DRSRPRX
| Q4 25 | $321.0M | $9.0B | ||
| Q3 25 | $326.0M | $8.9B | ||
| Q2 25 | $331.0M | $8.0B | ||
| Q1 25 | $335.0M | $7.6B | ||
| Q4 24 | $340.0M | $7.6B | ||
| Q3 24 | $345.0M | $7.6B | ||
| Q2 24 | $351.0M | $7.6B | ||
| Q1 24 | $356.0M | $6.1B |
股东权益DRSRPRX
| Q4 25 | $2.7B | $9.7B | ||
| Q3 25 | $2.6B | $9.6B | ||
| Q2 25 | $2.6B | $9.5B | ||
| Q1 25 | $2.6B | $9.8B | ||
| Q4 24 | $2.6B | $10.3B | ||
| Q3 24 | $2.5B | $10.3B | ||
| Q2 24 | $2.4B | $9.8B | ||
| Q1 24 | $2.4B | $9.9B |
总资产DRSRPRX
| Q4 25 | $4.5B | $19.6B | ||
| Q3 25 | $4.2B | $19.3B | ||
| Q2 25 | $4.1B | $18.3B | ||
| Q1 25 | $4.1B | $17.6B | ||
| Q4 24 | $4.2B | $18.2B | ||
| Q3 24 | $3.9B | $18.0B | ||
| Q2 24 | $3.8B | $17.7B | ||
| Q1 24 | $3.8B | $16.1B |
负债/权益比DRSRPRX
| Q4 25 | 0.12× | 0.92× | ||
| Q3 25 | 0.12× | 0.93× | ||
| Q2 25 | 0.13× | 0.84× | ||
| Q1 25 | 0.13× | 0.78× | ||
| Q4 24 | 0.13× | 0.74× | ||
| Q3 24 | 0.14× | 0.74× | ||
| Q2 24 | 0.15× | 0.78× | ||
| Q1 24 | 0.15× | 0.62× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $425.0M | $827.1M |
| 自由现金流经营现金流 - 资本支出 | $376.0M | — |
| 自由现金流率自由现金流/营收 | 35.5% | — |
| 资本支出强度资本支出/营收 | 4.6% | — |
| 现金转化率经营现金流/净利润 | 4.17× | 3.86× |
| 过去12个月自由现金流最近4个季度 | $227.0M | — |
8季度趋势，按日历期对齐
经营现金流DRSRPRX
| Q4 25 | $425.0M | $827.1M | ||
| Q3 25 | $107.0M | $702.6M | ||
| Q2 25 | $-28.0M | $364.0M | ||
| Q1 25 | $-138.0M | $596.1M | ||
| Q4 24 | $443.0M | $742.5M | ||
| Q3 24 | $59.0M | $703.6M | ||
| Q2 24 | $34.0M | $658.2M | ||
| Q1 24 | $-265.0M | $664.6M |
自由现金流DRSRPRX
| Q4 25 | $376.0M | — | ||
| Q3 25 | $77.0M | — | ||
| Q2 25 | $-56.0M | — | ||
| Q1 25 | $-170.0M | — | ||
| Q4 24 | $414.0M | — | ||
| Q3 24 | $47.0M | — | ||
| Q2 24 | $0 | — | ||
| Q1 24 | $-275.0M | — |
自由现金流率DRSRPRX
| Q4 25 | 35.5% | — | ||
| Q3 25 | 8.0% | — | ||
| Q2 25 | -6.8% | — | ||
| Q1 25 | -21.3% | — | ||
| Q4 24 | 42.2% | — | ||
| Q3 24 | 5.8% | — | ||
| Q2 24 | 0.0% | — | ||
| Q1 24 | -40.0% | — |
资本支出强度DRSRPRX
| Q4 25 | 4.6% | — | ||
| Q3 25 | 3.1% | — | ||
| Q2 25 | 3.4% | — | ||
| Q1 25 | 4.0% | — | ||
| Q4 24 | 3.0% | — | ||
| Q3 24 | 1.5% | — | ||
| Q2 24 | 4.5% | — | ||
| Q1 24 | 1.5% | — |
现金转化率DRSRPRX
| Q4 25 | 4.17× | 3.86× | ||
| Q3 25 | 1.49× | 2.44× | ||
| Q2 25 | -0.52× | 12.06× | ||
| Q1 25 | -2.76× | 2.50× | ||
| Q4 24 | 4.98× | 3.57× | ||
| Q3 24 | 1.04× | 1.29× | ||
| Q2 24 | 0.89× | 6.45× | ||
| Q1 24 | -9.14× | 139.10× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
DRS
暂无分部数据
RPRX
| Financial Royalty Assets | $592.4M | 95% |
| Royalty Income Other | $29.6M | 5% |
